The Burrill Report

The Burrill Report (April 29, 2013): Why Biotechs Need to Adapt to the Value-Based World(.MP3,12.53 Mb)

As healthcare systems move from fee-for-service to value-based models, biotech companies can’t rely on just addressing questions of safety and efficacy, but must consider how payers view the value of their products as well. We spoke to Glen Giovannetti, Ernst & Young’s Global Life Sciences Leader about why companies can’t afford to wait until launching their products to address questions of value, why data is becoming a key driver of value for products, and why most biotech companies remain in denial about operating in the evidence-based world that is emerging.











April 23, 2013
http://www.burrillreport.com/article-why_biotechs_need_to_adapt_to_the_value_based_world.html